Clinically targeted screening for congenital CMV - potential for integration into the National Hearing Screening...

Area of Science:

• Neonatal screening
• Public health
• Audiology

Background:

• Congenital cytomegalovirus (cCMV) is a significant cause of sensorineuronal hearing loss (SNHL) in newborns.
• Current UK policy does not include screening for cCMV, despite its impact on infant hearing.
• Early treatment with ganciclovir can mitigate progressive SNHL if initiated within the first month of life.

Purpose of the Study:

• To evaluate the potential of integrating congenital CMV (cCMV) screening into the existing UK Newborn Hearing Screening Programme (NHSP).
• To explore how screening, early diagnosis, and timely management of cCMV can be consolidated.
• To provide evidence for a clinically targeted screening approach for cCMV in the UK.

Main Methods:

• Discussion of the criteria for implementing screening programs.
• Analysis of the Newborn Hearing Screening Programme (NHSP) capabilities for early SNHL detection.
• Consideration of integrating cCMV screening into the NHSP framework.

Main Results:

• Congenital CMV (cCMV) meets established criteria for screening programs.
• The NHSP is effective in identifying SNHL at the earliest possible stage.
• Integrating cCMV screening into the NHSP is a viable option for the UK.

Conclusions:

• Early diagnosis and treatment of cCMV can prevent a portion of late-onset SNHL.
• Targeted screening via the NHSP offers a practical approach in the UK.
• This strategy can improve the diagnostic pathway and reduce long-term morbidity associated with cCMV.